ChinaBio Research

ChinaBio^® maintains a team of researchers in Shanghai, performing primary and secondary research on a variety of subjects of interest to companies in the life science industry:

• Therapeutics, diagnostics and medical devices
• Novel technology development in China
• Government funding activity
• Clinical trial activity in China
• VC investment in life science companies
• M&A/IPO activity
• Partnering/collaboration deals

Some of our key findings from our 2010 data include:

• VC investment in China life science exceeded $1B US for first time, up 3-fold from 2009
• Record year for IPOs with 33 offerings raising nearly $6B US
• M&A activity up 7-fold by dollar volume to $3.4B; average deal size up 3-fold to $70M, with several $100M+ deals
• Number of NME patents has increased 45% CAGR since 2000; now 3,200 NMEs patented in China

These and other proprietary data devloped by ChinaBio^® give us unique insights into China life science industry, and is used to build our proprietary databases and to support our consulting activities (see Consulting). 

Please contact us if you would like more information on the state of China life science.